Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Enveric Biosciences, Inc. Common Stock

ENVB

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.41 – $1.49
Volume 10,537
Market cap $6M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.45M
Price / earnings
—
Price / book
0.8×
Price / sales
—
EV / sales
—
EV / EBITDA
0.22×

Profitability

Earnings per share
-$2.70
Return on assets
-135.16%
Return on equity
-149.56%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
10.21×
Quick ratio
10.21×
Cash ratio
9.63×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.56M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ENVB, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.64M$1.25M$1.78M$1.43M$1.22M$1.36M$2.12M$1.2M
Research and development$1.36M$345.97K$372.18K$402.42K$1.26M$746.37K$967.4K$802.72K
Total operating expenses$3.03M$1.63M$2.19M$1.87M$2.52M$2.19M$3.17M$2.08M
Operating income-$3.03M-$1.63M-$2.19M-$1.87M-$2.52M-$2.19M-$3.17M-$2.08M
Interest expense-$292$0-$250$274-$132$0-$225-$217
Income before taxes-$3.03M-$1.63M-$2.19M-$1.87M-$2.52M-$2.18M-$3.15M-$2.08M
Income taxes$0$0$0$0$0$0$7.2K$0
Net income-$3.03M-$1.63M-$2.19M-$1.87M-$2.52M-$2.18M-$3.15M-$2.08M
Net income attributable to common shareholders-$3.03M-$1.63M-$4.04M-$3.39M-$2.52M-$2.18M-$3.15M-$2.08M
EBITDA-$2.99M-$1.6M-$2.15M-$1.83M-$2.48M-$2.11M-$3.09M-$2M
Basic earnings per share-$0.76-$1.08-$6.13-$10.81-$11.65-$14.58-$57.46-$43.10
Diluted earnings per share-$0.76-$1.08-$6.13-$10.81-$11.65-$14.58-$57.46-$43.10

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order

Enveric Biosciences (NASDAQ: ENVB) surged over 106% in premarket trading following President Trump's executive order directing federal agencies to accelerate approval timelines for psychedelic-based treatments. The administration also committed $50 million to ibogaine research. While momentum is improving with positive MACD signals, the stock remains 47.2% below its 200-day moving average, indicating the rally occurs within a longer-term downtrend.

Zacks Investment Research

New Strong Buy Stocks for April 17th

BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 28, 20251-for-12reverse split
Jan 29, 20251-for-15reverse split
Jul 15, 20221-for-50reverse split
Nov 25, 20191-for-25reverse split